ATE306924T1 - 2-substituierte 1-arylpiperazine als tachykinin- antagonisten und/oder serotonin-wiederaufnahme- hemmer - Google Patents

2-substituierte 1-arylpiperazine als tachykinin- antagonisten und/oder serotonin-wiederaufnahme- hemmer

Info

Publication number
ATE306924T1
ATE306924T1 AT02794786T AT02794786T ATE306924T1 AT E306924 T1 ATE306924 T1 AT E306924T1 AT 02794786 T AT02794786 T AT 02794786T AT 02794786 T AT02794786 T AT 02794786T AT E306924 T1 ATE306924 T1 AT E306924T1
Authority
AT
Austria
Prior art keywords
reuppost
arylpiperazine
serotonin
inhibitors
substituted
Prior art date
Application number
AT02794786T
Other languages
English (en)
Inventor
Giuseppe Alvaro
Maria Tranquillini
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE306924T1 publication Critical patent/ATE306924T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02794786T 2001-08-14 2002-08-13 2-substituierte 1-arylpiperazine als tachykinin- antagonisten und/oder serotonin-wiederaufnahme- hemmer ATE306924T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119797.9A GB0119797D0 (en) 2001-08-14 2001-08-14 Chemical compounds
PCT/EP2002/009066 WO2003015784A1 (en) 2001-08-14 2002-08-13 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors

Publications (1)

Publication Number Publication Date
ATE306924T1 true ATE306924T1 (de) 2005-11-15

Family

ID=9920365

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794786T ATE306924T1 (de) 2001-08-14 2002-08-13 2-substituierte 1-arylpiperazine als tachykinin- antagonisten und/oder serotonin-wiederaufnahme- hemmer

Country Status (9)

Country Link
US (1) US7214680B2 (de)
EP (1) EP1423117B1 (de)
JP (1) JP2005502655A (de)
AR (1) AR035110A1 (de)
AT (1) ATE306924T1 (de)
DE (1) DE60206781T2 (de)
ES (1) ES2247408T3 (de)
GB (1) GB0119797D0 (de)
WO (1) WO2003015784A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214832A1 (en) * 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
JP4775259B2 (ja) * 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
EP1707206A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Piperazinderivate zur inhibition von Beta-Sekretase, Cathepsin D, Plasmepsin ll und HIV-Protease und zur Behandlung von Malaria, Alzheimer und AIDS
GB0511063D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP1957450B1 (de) * 2005-12-01 2009-06-24 F.Hoffmann-La Roche Ag Inhibitoren des serotonintransporters (sert)
US7872022B2 (en) 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
ES2356098T3 (es) * 2006-08-17 2011-04-04 F. Hoffmann-La Roche Ag Derivados de arilpiperazina y usos de los mismos.
US20110092703A1 (en) 2007-08-10 2011-04-21 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
BRPI0908807A2 (pt) 2008-02-15 2015-07-28 Hoffmann La Roche Derivados de 3-alquil-piperazina e usos dos mesmos
WO2012124775A1 (ja) * 2011-03-16 2012-09-20 田辺三菱製薬株式会社 含窒素飽和複素環化合物
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
RU2752088C1 (ru) 2016-09-21 2021-07-22 Вектус Байосистемс Лимитед Композиции для лечения гипертензии и/или фиброза
CN111892544A (zh) * 2020-08-31 2020-11-06 南通大学 一种3-（氨基甲基）-4-（4-氟苯基）哌嗪-1-羧酸叔丁酯及其合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077293A (en) * 1990-06-29 1991-12-31 Bristol-Myers Squibb Co. 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
DE69628559T2 (de) 1995-04-07 2004-04-29 Schering Corp. Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
US6369063B1 (en) 1997-04-14 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
AU6896298A (en) 1997-04-14 1998-11-11 Cor Therapeutics, Inc. Selective factor xa inhibitors
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US7214680B2 (en) 2007-05-08
WO2003015784A1 (en) 2003-02-27
EP1423117A1 (de) 2004-06-02
JP2005502655A (ja) 2005-01-27
DE60206781T2 (de) 2006-06-01
EP1423117B1 (de) 2005-10-19
DE60206781D1 (de) 2006-03-02
AR035110A1 (es) 2004-04-14
US20040242592A1 (en) 2004-12-02
ES2247408T3 (es) 2006-03-01
GB0119797D0 (en) 2001-10-03

Similar Documents

Publication Publication Date Title
ES2867378T8 (es) Epinefrina inhalable
DE60331751D1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
ATE306924T1 (de) 2-substituierte 1-arylpiperazine als tachykinin- antagonisten und/oder serotonin-wiederaufnahme- hemmer
ATE392897T1 (de) Chinolinderivate als npy antagonisten
ATE390426T1 (de) Aminocyclische substituierte pyrrolopyrimidinderivate und pyrrolopyridinderivate
NO20034308L (no) Nye tyrokinase-inhibitorer
NO20041293L (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
NO20054433D0 (no) Methods and devices for building construction
NO20053569D0 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister
ITMI20021247A1 (it) Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
DE60203481D1 (de) Piperidinderivate als neurokinin 1 antagonisten
ATE469875T1 (de) Nk1-antagonisten
DE60326568D1 (de) Pendellager
ATE499096T1 (de) Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
ATE308323T1 (de) Diaminothiazole und ihre anwendung als cdk4 inhibitoren
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
ATE538093T1 (de) Substituierte 2-carbonylamino-6- piperidinaminopyridine und substituierte 1- carbonylamino-3-piperidinaminobenzole als 5-ht1f- agonisten
EP1740120A4 (de) Langzeitformulierungen von naltrexon und anwendungsverfahren
DE60230491D1 (de) Als ccr5-antagonisten verwendbare aryloxim-piperazine
DK1442050T3 (da) Lineære basiske forbindelser med NK-2-antagonistaktivitet samt formuleringer deraf
DE60133014D1 (de) H3 agonisten oder antagonisten
ATE441647T1 (de) N-amidderivate von 8-azabicycloä3.2.1üoct-3-yl als ccr1-antagonisten
DE60317709D1 (de) Substituierte 1-piperidin-3-yl-4-piperidin-4-yl-piperazin-derivate und ihre verwendung als neurokinin-antagonisten
DE60135471D1 (de) H3 agonisten oder antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties